Maes v. Folberg

504 F. Supp. 2d 339, 2007 U.S. Dist. LEXIS 47657, 2007 WL 1958575
CourtDistrict Court, N.D. Illinois
DecidedJune 27, 2007
Docket06 C 6849
StatusPublished
Cited by3 cases

This text of 504 F. Supp. 2d 339 (Maes v. Folberg) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maes v. Folberg, 504 F. Supp. 2d 339, 2007 U.S. Dist. LEXIS 47657, 2007 WL 1958575 (N.D. Ill. 2007).

Opinion

MEMORANDUM OPINION AND ORDER

JAMES B. MORAN, Senior District Judge.

Plaintiff Lou Ann Maes brought this action against Robert Folberg and the Board of Trustees for the University of Illinois, claiming violations of her rights under the Family Medical Leave Act, 29 U.S.C. § 2611 et seq. (“FMLA”), the First and Fourteenth Amendments, and state law. Judge Shadur, sitting for this court, received defendants’ motion to dismiss and strike, made some preliminary rulings, and allowed plaintiff an opportunity to respond.

*342 After an analysis of the parties’ arguments, we deny in part defendants’ motion to dismiss and strike.

BACKGROUND

In reviewing a motion to dismiss under Rule 12(b)(6) of the Federal Rules of Civil Procedure, we must accept the complaint’s well-pleaded factual allegations as true, including the inferences reasonably drawn from them. McDonald v. Household Int’l, 425 F.3d 424, 425 (7th Cir.2005). Although the Supreme Court, in deciding a motion to dismiss an antitrust claim, recently held that a plaintiff is obligated to provide the grounds of his entitlement for relief in order to survive a 12(b)(6) motion (Bell Atlantic Corp. v. Twombly, — U.S.-, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)), the Seventh Circuit has consistently, and recently, articulated its view that Fed. R.Civ.P. 8(a) is a permissive pleading standard. See e.g., Bowers v. Federation Internationale de l'Automobile, 489 F.3d 316 (7th Cir.2007) (post-Twombly opinion indicating that dismissal is appropriate only “if a plaintiff does not allege such a claim or if it appears beyond doubt that the plaintiff can prove no set of facts that would entitle her to relief’); Vincent v. City Colleges of Chicago, 485 F.3d 919, 923 (7th Cir.2007) (“Civil Rule 8 calls for a short and plain statement; the plaintiff pleads claims, not facts or legal theories.... [T]he possibility that facts to be adduced later, and consistent with the complaint, could prove the claim, is enough for the litigation to move forward”). The following facts are taken from plaintiffs complaint.

Plaintiff is a licensed physician, certified by the American Board of Pathology in Clinical Pathology and Transfusion Medicine. In 2004, plaintiff came to the University of Illinois at Chicago (“UIC”) Medical Center as a Visiting Director of Clinical Pathology. In 2005, she became Director of Transfusion Medicine and Interim Director of Clinical Microbiology. She remained in that position until October, 2005, when the events precipitating this lawsuit transpired. Plaintiff remains an associate professor in the UIC College of Medicine. Defendant Folberg is a physician licensed in pathology and ophthalmology, and the Chair of the Pathology Department at the UIC Medical Center. In that capacity, Folberg acted as plaintiffs supervisor. Defendant Board of Trustees of UIC is a public corporation established to operate and administer the UIC, including the UIC Medical Center.

In her position at the UIC Medical Center, plaintiff was responsible for ensuring the safe and effective operation of the UIC Medical Center Blood Bank. In its capacity as a health care provider, the UIC Medical Center must submit to various inspections and maintain accreditations or certifications from various governmental and quasi-governmental agencies, including the Food and Drug Administration (“FDA”), the Joint Commission on Accreditation of Healthcare Organization (“JCAHO”), and the College of American Pathologists and the American Association of Blood Banks (“AABB”). Collections taken at the Blood Bank Donor Room (“BBDR”), a component of the UIC Blood Bank, are intensively regulated by the FDA and monitored by the AABB. According to plaintiff, such regulation requires a comprehensive process of documentation and development of procedures and monitoring, “including, but not limited to, the development of training regimens, standard operating procedures (SOP’s), regimens for equipment, laboratory, environmental, processing and blood product quality control, protocols for screening donors, collecting and testing blood, storage and notification to donors and recipients of positive infectious disease test results or other issues affecting patient safety” (cplt., ¶ 13). Plaintiff re *343 ceived complimentary notations about her work at the UIC Medical Center and was promoted to a tenure track position in August, 2005.

In July, 2005, an employee of the Blood Donor Center submitted her resignation, in which she made allegations of misconduct against the associate director of the Blood Bank and Blood Bank Hemotherapy Center. The allegations suggested that prior to plaintiffs arrival the Blood Bank was being run in contravention of SOPs and safe practices. After an investigation into such allegations, plaintiff discovered falsified records of platelet donors, improper quality control, and inadequate training. Upon further investigation, plaintiff uncovered a number of other problems, including several violations of federal FDA regulations, along with violations of federal Medicare/Medicaid regulations concerning the falsification of records. On September 1, 2005, plaintiff notified the FDA of the results of her investigation and informed the FDA that she had temporarily closed the BBDR. Thereafter, the FDA conducted its own investigation, finding unsatisfactorily completed temperature logs, a dirty centrifuge, messy documentation, improper maintenance records and record-keeping, and problems in the content of various SOPs.

After completion of the FDA inspection, plaintiff met with Folberg and others at an FDA summation meeting, where Folberg interrogated plaintiff about her communications with the FDA and ordered that she not have any further communication without his approval. At a similar meeting a week later, Folberg berated plaintiff about her “behavior” with the FDA, and intimated that she should resign as Director of Clinical Pathology. Although plaintiff attempted to correct the deficiencies of the Blood Bank, Folberg interfered by not allowing additional hires and not requiring the associate director to participate in the upgrades. Upon receiving a phone call at home from Folberg insisting she resign as Director of Clinical Pathology, plaintiff wrote a resignation e-mail using Folberg’s suggested language. In subsequent days, Folberg removed plaintiff as a co-investigator of a clinical study, limited her access to a visiting quality inspector, and excluded her from an emergency meeting of the BBDR staff. Plaintiffs complaints to Fol-berg’s superiors went unheeded; they acted to support the retaliation and failed to correct the reporting failures uncovered by plaintiff.

On May 1, 2006, plaintiff became seriously ill with a life-threatening eye disease, requiring her to miss work for approximately five weeks. Her leave was approved under the FMLA. Upon returning to work on June 5, 2006, plaintiff received two letters signed by Folberg.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lugg v. Sutton
368 F. Supp. 3d 1257 (C.D. Illinois, 2019)
Woofbeach, Inc. v. Holland
N.D. Illinois, 2017
Roger Lange v. Dan McGinnis
644 F. App'x 672 (Sixth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
504 F. Supp. 2d 339, 2007 U.S. Dist. LEXIS 47657, 2007 WL 1958575, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maes-v-folberg-ilnd-2007.